News Focus
News Focus
Followers 84
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: biopharm post# 241924

Monday, 06/27/2016 5:38:05 PM

Monday, June 27, 2016 5:38:05 PM

Post# of 347009

Nagata is to Phosphatidylserine as Dmitry Gabrilovich is to MDSC's...and WHO knows, maybe many feared that Peregrine interfearedon many other Big Pharmas legacy.




Nagata is still at it and all the talk about PS exposure will all lead to PS Targeting

Cell Death
Gordon Research Conference

New Concepts in Cell Death Research: From Basic Mechanisms to Clinical Opportunities

Dates
July 3-8, 2016
Location
PGA Catalunya Business and Convention Centre
Girona, Spain

Site Information

Organizers
Chair:
Henning Walczak

Vice Chair:
Marion MacFarlane

6:00 pm - 6:15 pm Shigekazu Nagata (Osaka University, Japan)
"Molecular Mechanism of Apoptotic Phosphatidylserine Exposure"

9:40 am - 9:55 am Peter Vandenabeele (VIB, University of Ghent, Belgium)
"Role of RIPK3 in Cell Death and Inflammation"

https://www.grc.org/programs.aspx?id=12477


"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y